rupiya.io
⠋Loading...
0%
❯ Analyzing price movements...
Emcure Pharmaceuticals Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Emcure Pharmaceuticals Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Sales | ₹4,717 Cr | ₹5,049 Cr | ₹5,033 Cr | ||||
| Expenses | ₹3,968 Cr | ₹4,340 Cr | ₹3,817 Cr | ||||
| Operating Profit | ₹749 Cr | ₹708 Cr | ₹1,216 Cr | ||||
| OPM % | 16.0% | 14.0% | 24.0% | ||||
| Other Income | ₹72 Cr | ₹-25 Cr | ₹-159 Cr | ||||
| Depreciation | ₹267 Cr | ₹321 Cr | ₹250 Cr | ||||
| Interest | ₹223 Cr | ₹257 Cr | ₹155 Cr | ||||
| Profit Before Tax | ₹331 Cr | ₹105 Cr | ₹652 Cr | ||||
| Tax | ₹331 Cr | ₹105 Cr | ₹652 Cr | ||||
| Net Profit | ₹209 Cr | ₹101 Cr | ₹419 Cr | ||||
| EPS (₹) | 10.8 | 4.6 | 23.2 | ||||
| Dividend Payout % | 32% | 54% | 4% |
Register free to see 4 more years.
| Quarter | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹1,556 Cr | ₹1,663 Cr | ₹1,668 Cr | ₹1,771 Cr | |||||||
| Expenses | ₹1,261 Cr | ₹1,334 Cr | ₹1,374 Cr | ₹1,460 Cr | |||||||
| Operating Profit | ₹296 Cr | ₹329 Cr | ₹294 Cr | ₹311 Cr | |||||||
| OPM % | 19.0% | 20.0% | 18.0% | 18.0% | |||||||
| Depreciation | ₹67 Cr | ₹70 Cr | ₹84 Cr | ₹91 Cr | |||||||
| Interest | ₹52 Cr | ₹59 Cr | ₹61 Cr | ₹65 Cr | |||||||
| Net Profit | ₹141 Cr | ₹146 Cr | ₹120 Cr | ₹121 Cr | |||||||
| EPS (₹) | 7.2 | 7.7 | 6.3 | 6.4 |
Register free to see 7 more quarters.
| Period | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹181 Cr | ₹181 Cr | ₹181 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹1,654 Cr | ₹1,731 Cr | ₹2,092 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹2,128 Cr | ₹2,327 Cr | ₹2,310 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹1,613 Cr | ₹1,721 Cr | ₹2,184 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹5,577 Cr | ₹5,960 Cr | ₹6,768 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹2,247 Cr | ₹2,382 Cr | ₹2,188 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹2,749 Cr | ₹3,093 Cr | ₹4,278 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹5,577 Cr | ₹5,960 Cr | ₹6,768 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 4 more years.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2020 | ₹444 Cr | ₹-409 Cr | ₹-735 Cr | — |
| Mar 2021 | ₹500 Cr | ₹-168 Cr | ₹-301 Cr | — |
| Mar 2022 | ₹704 Cr | ₹-256 Cr | ₹-189 Cr | — |
| Mar 2023 | ||||
| Mar 2024 | ||||
| Mar 2025 | ||||
| Mar 2026 |
Register free to see 4 more years.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +8.45% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.74% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -5.78% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +7.74% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +3.69% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.